Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient
- 1 Medical Oncology Unit, Department of Oncology, University of Palermo, Palermo, Italy
- 2 Medical Oncology Unit, Department of Oncology, University of Palermo, Palermo, Italy
- 3 Medical Oncology Unit, La Maddalena Clinic for Cancer, University of Palermo, Palermo, Italy
- 4 Medical Oncology Unit, La Maddalena Clinic for Cancer, University of Palermo, Palermo, Italy
Abstract
Background : Agent targeting HER-2 pathway plus chemotherapy has represented a major progress in the management of patients with breast cancer. However , the role of late-line treatment in heavily pretreated patients is still largely unclear. In the last decade , nab-paclitaxel has shown significant activity and good toxicity profile in metastatic breast cancer. Case Presentation : We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line therapy. She had previously received first-line paclitaxel and trastuzumab, second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral capecitabine and lapatinib. Clinical and radiological staging showed progression at bone, skin and soft-tissue. The patient received weekly nab-paclitaxel plus trastuzumab. Massive objective response was clinically and PET documented which lasted 8 months. Tolerance to treatment was fairly good as well as cardiac safety. Conclusion : To the best of our knowledge, this is the first reported case of efficacy of nab-paclitaxel in combination with trastuzumab as fifth-line of treatment in a patient with metastatic HER-2 positive breast cancer.
- Blows, F.M., Driver, K.E., Schmidt, M.K., Broeks, A., van Leeuwen, F.E., Wesseling, J., et al. (2010) Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtypeand Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. PLoS Medicine, 7, e1000279.
- Baselga, J., Cortés, J., Kim, S.B., Im, S.A., Hegg, R., Im, Y.H., Roman, L., Pedrini, J.L., Pienkowski, T., Knott, A., Clark, E., Benyunes, M.C., Ross, G. and Swain, S.M. for the CLEOPATRA Study Group (2012) Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. New England Journal of Medicine, 366, 109-119. https://doi.org/10.1056/NEJMoa1113216
- Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J., Pegram, M., Oh, D.Y., Diéras, V., Guardino, E., Fang, L., Lu, M.W., Olsen, S., Blackwell, K., for the EMILIA Study Group (2012) Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine, 367, 1783-1791. https://doi.org/10.1056/NEJMoa1209124
- Montemurro, F., Donadio, M., Clavarezza, M., Redana, S., Jacomuzzi, M.E., Valabrega, G., et al. (2006) Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing during Trastuzumab Based Therapy. Oncologist, 11, 318-324. https://doi.org/10.1634/theoncologist.11-4-318
- Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P. et al. (2005) Phase III Trial of Nanoparticle Albumin-Boundpaclitaxel Compared with Polyethylated Castor Oil-Based Paclitaxelin Women with Breast Cancer. Journal of Clinical Oncology, 23, 7794-7803. https://doi.org/10.1200/JCO.2005.04.937
- Gradishar, W.J., Krasnojon, D., Cheporov, S., Makhson, A.N., Manikhas, G.M., Clawson, A., et al. (2009) Significantly Longer Progression-Free Survival with Nab-Paclitaxel Compared with Docetaxel as First-Line Therapy for Metastatic Breast Cancer. Journal of Clinical Oncology, 27, 3611-3619. https://doi.org/10.1200/JCO.2008.18.5397
- Rugo, H.S., Barry, W.T., Moreno-Aspitia, A., Lyss, A.P., Cirrincione, C., Leung, E., Mayer, E.L., Naughton, M., Toppmeyer, D., Carey, L.A., Perez, E.A., Hudis, C. and Winer, E.P. (2015) Randomized Phase III Trial of Paclitaxel Once per Week Compared with Nanoparticle Albumin-Bound Nab-Paclitaxel Once per Week or Ixabepilone with Bevacizumab as First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology, 33, 2361-2369. https://doi.org/10.1200/JCO.2014.59.5298
- Jackischa, C., Lückb, H.J., Untchc, M., Bischoffd, J., Müllere, V., Schmidtf, M., Thillg, M. and Kiechle, M. (2012) Weekly Nab-Paclitaxel in Metastatic Breast Cancer—Summary and Results of an Expert Panel Discussion. Breast Care, 7, 137-143. https://doi.org/10.1159/000338273